February 13, 2023: In testimony before CMS MEDCAC, NCHR strongly supported the new proposals to improve the quality of research needed to decide Medicare coverage evidence. We especially appreciate the focus on clinically meaningful benefits for patients that are representative of Medicare beneficiaries
Read More »On Health Policy
NCHR Comments on USPTO-FDA Collaboration and Engagement
February 6, 2023: NCHR’s public comments strongly support FDA’s decision to prioritize USPTO-FDA collaboration. Access to generic drugs and biosimilars is critically important and abuse of the patent system remains a major barrier. We are hopeful that meaningful collaboration between the FDA and the USPTO will result in substantial improvements.
Read More »NCHR Comments on HHS Proposed Rule Regarding Confidentiality of Substance Use Disorder (SUD) Patient Records
January 31, 2023: NCHR’s public comment criticizes the HHS plan to align privacy standards with HIPAA instead of Part 2. We are concerned that loss of privacy for patients with substance abuse disorder (SUD) could stigmatize them or discourage them from seeking treatment.
Read More »NCHR Statement on Transparency of Children’s Clinical Trials
January 24, 2023: A new report finds that 3,627 American children participated in clinical trials whose results remain hidden. This is not ‘only’ unethical – it’s illegal.
Read More »NCHR Comments on EPA’s Proposed Finding that Lead Emissions from Aircraft Engines using Leaded Fuel May Endanger Public Health
January 17, 2023: The presence of lead in aircraft engines has a significant, negative effect on public health, and we enthusiastically agree with the proposed EPA finding in support of these conclusions. These findings should be finalized as soon as possible to give EPA the authority to set aircraft emission standards for lead under section 231 of the Clean Air Act.
Read More »